Dr Martin Cross

Medicines Australia Chairman
'Timely access to affordable medicines for all Australians - Certainty the key to the future.'
Wednesday, 19 March 2014
Arrive from 11.30am, lunch 12 noon, speaker 12.30 concludes 1.30pm

Registrations for this event are now closed. Please contact reception for further details.

The Pharmaceutical Benefits Scheme (PBS) is a national treasure and for sixty five years has ensured universal, timely access to cost effective medicines to the benefit of all Australians. Over the last eight years, in partnership with the research and development industry, both the Coalition and Labor governments have introduced major reforms of the PBS. The reforms have resulted in a significant decrease in the growth of the cost of the PBS to the point where the PBS budget declined by 3.5% in the last financial year. These reforms are having a negative impact on the medicines industry and unintended consequences for the future access to the latest medicines. Pragmatic solutions are now required to ensure Australians continue to have universal, timely access to the latest medicines and the industry remains a strong contributor to the wealth as well as the health of the nation.

Dr Martin Cross became the Appointed Chairman of Medicines Australia on the 4th November 2013.

Martin’s career spans nearly 30 years in the prescription medicines industry. His early career was in the UK before he gained considerable international experience in global roles and in Japan. Martin started work in Australia in 2003 and became an Australian citizen in 2008. Prior to becoming the Chairman of Medicines Australia he has been the Managing Director of two major pharmaceutical companies in Australia, on the board and executive of Medicines Australia and Chairman of the GMiA. From 2012 to 2013 Martin served as the Chairman of the Pharmaceuticals Industry Council, the peak body for Australia’s pharmaceutical and biotechnology industries.

Martin graduated with a PhD in microbiology from Aberdeen University Scotland and has undertaken postgraduate study at INSEAD and the Harvard Business School and is a Fellow of the Australian Institute of Company Directors.